Lupin gets FDA nod for generic Renvela

Adults and children six years of age and older with chronic disease on dialysis will soon have a new generic treatment to control serum phosphorus.

The Food and Drug Administration has given its approval for Lupin’s sevelamer carbonate tablets, in a dosage strength of 800 mg.

The product is the generic of Genzyme’s Renvela.

Sevelamer carbonate tablets had a market value of approximately $348 million, according to IQVIA September 2020 data.